$VIR

Vir Biotechnology, Inc.

No enriched coverage for $VIR in the last 7 days.

No SEC Form 4 filings for $VIR in the last 30 days.

Low

Vanguard Group Inc. Reduces Stock Position in Vir Biotechnology, Inc. $VIR

Vanguard Group Inc. decreased its holding in Vir Biotechnology, Inc. by 2.0% in the fourth quarter but remains the largest disclosed shareholder with 12.55 million shares. Despite a weak latest quarter with a significant EPS loss and revenue miss, analysts maintain a "Moderate Buy" consensus rating with a target price of $20.25. Insider selling activity also occurred recently, with the stock trading around $9.09.

Vir Biotechnology (VIR) CEO shifts 467,064 shares into family trust

Vir Biotechnology's President & CEO, Marianne De Backer, has restructured her common stock holdings, reclassifying a total of 467,064 shares into a family trust for tax and estate planning. This transaction, reported via Form 4, involves two entries of 233,532 shares each, shifting ownership without consideration rather than a market buy or sell. Following the changes, she holds 714,613 direct shares and 286,650 indirect shares through the Ureel-De Backer Family Trust.

VDH staff initially wanted to deny new Chesterfield HCA hospital. Why did the commissioner approve it?

Staff at the Virginia Department of Health initially recommended denying HCA Healthcare's request for a new hospital in Chesterfield County, citing no demonstrated need and hindering competition. However, State Health Commission Dr. Cameron Webb ultimately approved the project, along with two others, following an adjudication officer's recommendation, which highlighted anticipated population growth and improved access to care in the area. This decision will significantly increase bed capacity in Chesterfield County with new facilities from Bon Secours, VCU Health, and HCA Healthcare.